Hematological Malignancies

Phase II Pivotal Study of BV Patients with R/R HL post ASCT

Maximum tumor reduction per IRF

SD PR CR PD

Tumour Size (% Change from Baseline)

Younes A et al, J Clin Oncol 2012;30: 2183-2189. Reused with permission. ©2012 Journal of Clinical Oncology. American Society of Clinical Oncology. All rights reserved.